The tech giant has struck a new buyout deal in the growing market for clinical trials software.
Medidata Solutions ($MDSO) has impressed industry watchers with strong financial performance and sunny projections for 2012, earning the company some positive buzz in the press and at least one stock upgrade from "hold" to "buy."
The National Cancer Institute (NCI), which is part of the NIH, is joining forces with Health Level Seven International (HL7) to connect trials data with electronic health records, the group announced last month.
Slow patient recruitment looms as one of the biopharma industry's most notorious boogiemen, delaying the start of trials and prolonging the costly development process. Moffitt Cancer Center in...
As projects generate larger quantities of more complex data, IT needs to becomes an increasingly important part of research of any kind, but particularly personalized medicine.
Appistry, a recent entrant in the game for providing analytics for genomics data, has picked up a partnership with the University of Missouri. The university is tapping Appistry's system called
Oracle ($ORCL) wants to help drug researchers tap and analyze genomic data that are vital to the development of personalized therapies, which have already become key weapons in the war on cancer. The
Drug developers have been aiming to maximize efficiency in notoriously expensive clinical trials, and they have increased investments in clinical trial management system (CTMS) software to streamline
Dublin-based Clinical Trial EndPoint (CTEP) has found its sweet spot. With Oracle ($ORCL) glomming up big chunks of the clinical trials market for electronic data capture (EDC) software, smaller
Electronic health records contain lots of data on patents and their disease states, yet bringing that information into the hands of drug researchers has been a big challenge. Oracle ($ORCL) is taking